# Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders

> **NCT01725542** · PHASE2 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 75 (actual)

## Conditions studied

- HCV-HIV Co-Infection

## Interventions

- **DRUG:** Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT01725542
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-06
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2014-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01725542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01725542, "Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01725542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*